OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-888 for the treatment of Pancreatic Cancer. OBI-888 is a first in class monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA® (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Patients at Hunt Regional Medical Center in Greenville, Texas can now access industry leading interactive features on their patient-room televisions, thanks to the hospital’s launch this month of Allen Technologies’ E3 Patient Engagement Solution.

American Academy of Orthopaedic Surgeons issued the following announcement on Nov. 16.A new review article published in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) finds arthroscopic (joint replacement or reconstruction) management could be a promising option for young, active patients diagnosed with GHOA.

Pioneers in reproductive medicine to recruit patients for clinical trial of new method of testing embryos for chromosome abnormalities

Guidelines focus on lifestyle and behavioral management, pharmacologic approaches, and strategies for avoiding and treating diabetes-related complications

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued a narrated scientific white paper titled: “The critical importance of selectivity when developing antibody therapies for Alzheimer’s disease.”

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF), for the treatment of pulmonary alveolar proteinosis (PAP).

Alkermes plc (Nasdaq: ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), met to review the company's New Drug Application (NDA) for ALKS 5461.

The U.S. Food and Drug Administration permitted marketing of two devices that provide real-time location of parathyroid tissue during surgical procedures such as thyroidectomy (surgery to remove all or part of the thyroid) and parathyroidectomy (surgery to remove one or more parathyroid glands).

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new therapies to treat cystic fibrosis (CF).

New Assays empower Clinicians to more quickly make the right diagnosis at the point-of-care and prescribe the right treatment

The American Brain Tumor Association (ABTA), the nation's first nonprofit organization dedicated to brain tumor education and research, is now accepting Letters of Intent (LOI) for three research funding opportunities.

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack.

The Leukemia & Lymphoma Society (LLS) continues to lead cutting-edge research to advance treatments for myeloma and lymphoma. Adding to the momentum, the organization announced a $1,175,000 commitment by the Schwartz Ward Family Foundation (SWFF) of Chicago to support two unique research initiatives including a novel therapy for a rare form of lymphoma and an innovative immunotherapy approach for multiple myeloma.

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of patients with B-cell malignancies.

Long-term care facilities play a critical role in caring for the needs of a growing aging population with a lengthening lifespan.

Agreement Establishes a New Stronghold in a Rapidly Expanding Fertility Market

Montefiore’s outstanding stroke care has been recognized by an Advanced Comprehensive Stroke Center designation, meaning that the highest standards of lifesaving stroke care are close to home for millions of New Yorkers.

Research shows adding Abbott's High Sensitive Troponin-I diagnostic test to doctors' existing standard of care can help more accurately determine a person's chances of a heart attack or other cardiac event potentially months to years in advance